Clinical Trials

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.


Study ID
Bristol-Myers Squibb CA045-001

NCT Number
NCT03635983 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0565

Principle Investigator
Dr. Andrew Pecora

Phase
III

Sponsor
Bristol-Myers Squibb


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now